1. Home
  2. TVRD vs BETR Comparison

TVRD vs BETR Comparison

Compare TVRD & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • BETR
  • Stock Information
  • Founded
  • TVRD 2017
  • BETR 2014
  • Country
  • TVRD United States
  • BETR United States
  • Employees
  • TVRD N/A
  • BETR N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • BETR Finance: Consumer Services
  • Sector
  • TVRD Health Care
  • BETR Finance
  • Exchange
  • TVRD Nasdaq
  • BETR Nasdaq
  • Market Cap
  • TVRD 246.5M
  • BETR 203.4M
  • IPO Year
  • TVRD N/A
  • BETR N/A
  • Fundamental
  • Price
  • TVRD $33.88
  • BETR $24.99
  • Analyst Decision
  • TVRD Strong Buy
  • BETR
  • Analyst Count
  • TVRD 5
  • BETR 0
  • Target Price
  • TVRD $59.20
  • BETR N/A
  • AVG Volume (30 Days)
  • TVRD 22.1K
  • BETR 72.8K
  • Earning Date
  • TVRD 08-14-2025
  • BETR 11-12-2025
  • Dividend Yield
  • TVRD N/A
  • BETR N/A
  • EPS Growth
  • TVRD N/A
  • BETR N/A
  • EPS
  • TVRD N/A
  • BETR N/A
  • Revenue
  • TVRD N/A
  • BETR $130,672,000.00
  • Revenue This Year
  • TVRD N/A
  • BETR $55.38
  • Revenue Next Year
  • TVRD N/A
  • BETR $71.18
  • P/E Ratio
  • TVRD N/A
  • BETR N/A
  • Revenue Growth
  • TVRD N/A
  • BETR 69.42
  • 52 Week Low
  • TVRD $8.13
  • BETR $7.71
  • 52 Week High
  • TVRD $36.71
  • BETR $25.94
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 66.16
  • BETR 73.89
  • Support Level
  • TVRD $29.33
  • BETR $23.65
  • Resistance Level
  • TVRD $31.88
  • BETR $25.37
  • Average True Range (ATR)
  • TVRD 2.09
  • BETR 1.49
  • MACD
  • TVRD 0.49
  • BETR 0.19
  • Stochastic Oscillator
  • TVRD 69.21
  • BETR 88.30

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.

Share on Social Networks: